SR-14968 Stats & Data

SR-14968 is sold only as a research chemical with no human clinical data. Animal and in vitro work suggest G-protein-biased μOR agonism, but in vivo still produces respiratory depression at higher doses; therefore the classic opioid risks remain, particularly with polydrug use. Batch-to-batch potency appears highly variable by user reports; some describe active effects at 5–15 mg sublingual while others report limited effects below 50–100 mg orally. A recurring community hazard is a delayed or wave-like come-up (peaks 4–8+ hours post-dose), which makes early redosing especially risky due to stacking and late-onset oversedation. Naloxone should be carried and administered for suspected opioid overdose; multiple doses may be required, and sedation from non-opioid adulterants (e.g., xylazine) will not be reversed — always call emergency services. Avoid combining with other depressants (benzos, alcohol, GHB/GBL, other opioids, gabapentinoids); these combinations markedly increase the risk of respiratory compromise. Because supply chains for new opioid RCs have been targeted by scammers and adulteration is common in unregulated markets, avoid sharing personal/financial information, be skeptical of unsolicited vendors, and prefer accredited drug checking where available. For measuring, use a 0.001 g scale; consider volumetric dosing and perform a 1–2 mg allergy test, then wait a full day before any additional dosing to detect delayed effects. Do not inject; solvent, excipient, and sterility unknowns greatly increase harm. People attempting to self-manage withdrawal should recognize dependence and tolerance can still occur with biased agonists; medical supervision is strongly recommended.